家庭参与谵妄预防、识别与管理的可行性与可接受性试点随机对照试验:ACTIVATE研究
该试点随机对照试验在两家加拿大ICU纳入患者-家庭配对,评估家庭实施谵妄预防、识别和管理干预的可行性。干预包括谵妄教育和家庭使用的检查表(含预防/管理策略及Sour Seven识别工具),对照为标准照护。2020年1月至2023年6月新冠疫情期间,197对中64对(32%)同意参与,75%家庭完成ICU内问卷,38%完成所有随访;干预组家庭谵妄知识较基线增加,19名家庭中8名(42%)用Sour Seven识别出谵妄;3个月随访时7名家庭成员有显著焦虑、5名有显著抑郁;ICU查房观察显示谵妄讨论有限。结论为家庭实施谵妄照护可行,但受疫情限制家庭在场影响,需正式试验评估有效性。
要点
- 两家加拿大ICU试点RCT中,197对患者-家庭配对仅64对(32%)同意参与,招募受新冠疫情期间家庭在场限制影响。
- 75%家庭完成ICU内问卷,但仅38%完成全部随访,提示家庭参与谵妄照护的数据收集困难。
- 干预组家庭谵妄知识较基线增加并参与预防策略,19名家庭成员中8名(42%)用Sour Seven识别出谵妄。
- 3个月随访时7名家庭成员有显著焦虑、5名有显著抑郁,提示家庭参与照护的心理负担需关注。
- ICU查房观察显示谵妄讨论有限,作者认为需正式试验并调整流程以简化数据收集、加强家庭-照护团队合作。
适用人群与场景
- 纳入患者-家庭配对;患者无原发性脑损伤,Richmond躁动-镇静评分≥-3,预期ICU停留至少24小时以完成所有研究评估。
- 研究在两家加拿大ICU进行,时间为2020年1月至2023年6月新冠疫情期间。
诊断标准与关键阈值
- 使用Sour Seven工具由家庭成员识别谵妄。
处置流程与药物剂量
- 干预组家庭接受谵妄教育,并使用家庭实施的检查表,包含预防/管理策略和检测工具(Sour Seven)。
- 对照组接受标准照护。
研究设计与关键结果
- 试点随机对照试验,197对患者-家庭配对中64对(32%)同意参与;75%家庭完成ICU内问卷,38%完成所有随访。
- 干预组家庭成员谵妄知识较基线增加,并参与预防策略;19名家庭成员中8名(42%)使用Sour Seven识别出谵妄。
- 3个月随访时,7名家庭成员有显著焦虑,5名有显著抑郁。
- ICU查房观察显示谵妄讨论有限。
证据类型、等级与局限
- 证据类型:试点随机对照试验。
- 局限:招募困难;受新冠疫情期间家庭在场限制影响;仅38%完成所有随访;作者指出需正式试验并调整流程以简化数据收集和加强家庭-照护团队合作。
对床旁实践的改变
- 作者认为家庭实施的谵妄照护在ICU环境中可行,但新冠疫情期间家庭在场限制的影响不可忽视。
- 作者指出需进行假设检验的正式试验,并调整流程以简化数据收集、加强家庭与照护团队的合作,以全面评估有效性。
指南或共识出处
- 临床试验注册号:NCT04099472。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES BACKGROUND: Delirium remains frequently undetected by healthcare providers; partnering with family may be a novel way to identify and manage delirium. This study explores the feasibility of a family-administered intervention for delirium prevention, detection, and management.
DESIGN: Pilot randomized controlled trial.
SETTING: Two Canadian ICUs.
SUBJECTS: Patient-family pairs (dyads) were included. Eligible patients had no primary brain injury, a Richmond Agitation-Sedation Scale score of greater than or equal to -3, and were expected to remain in the ICU for at least 24 hours to complete all study assessments.
INTERVENTIONS: Dyads were randomly assigned to either standard care (control) or the intervention, which included delirium education and family-administered checklists with prevention/management strategies and a detection tool ("Sour Seven").
MEASUREMENTS AND MAIN RESULTS: Outcomes included feasibility indicators, enrollment and completion rates, and psychological outcomes (Generalized Anxiety Disorder-7, Patient Health Questionnaire-9, and the Kessler Psychologic Distress (K-10) scales in the ICU and at 1- and 3-month follow-ups. Between January 2020 and June 2023, during the height of the COVID pandemic, 197 patient-family pairs were approached, with 64 (32%) consenting to participate; participation required both the patient and a family member. Despite recruitment challenges, 75% of families completed in-ICU questionnaires, and 38% completed all follow-ups. The family members in the intervention group demonstrated increased delirium knowledge compared with baseline delirium knowledge, and engagement in prevention strategies, with 8 of 19 (42%) family members identifying delirium using the Sour Seven. At the 3-month follow-up, seven family members showed significant anxiety, and five showed significant depression. Observations of ICU rounds revealed limited delirium discussions.
CONCLUSIONS: This pilot study demonstrated the feasibility of family-administered delirium care in ICU settings. However, the likely impact of the COVID-19 pandemic cannot be overlooked. The study faced recruitment challenges and demonstrated the difficulties of family involvement in delirium care, particularly during restricted family presence. A full evaluation of effectiveness requires a hypothesis-testing trial with procedural adjustments to streamline data collection and strengthen family-care team partnerships.
TRIAL REGISTRATION: Clinicaltrials.gov (NCT04099472).
参考来源
- Fiest KM, Krewulak KD, Sept BG, et al. A Pilot Randomized Controlled Trial Assessing the Feasibility and Acceptability of Family-Partnered Delirium Prevention, Detection, and Management in Critically Ill Adults: The Activating Family Caregivers in the Identification Prevention and Management of Delirium (ACTIVATE) Study. Crit Care Explor. 2025. PMID: 40844707. doi:10.1097/CCE.0000000000001287
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。